| __timestamp | United Therapeutics Corporation | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 242549000 | 855506000 |
| Thursday, January 1, 2015 | 245098000 | 996170000 |
| Friday, January 1, 2016 | 147600000 | 1047690000 |
| Sunday, January 1, 2017 | 264600000 | 1324625000 |
| Monday, January 1, 2018 | 357900000 | 1416476000 |
| Tuesday, January 1, 2019 | 1182600000 | 1754540000 |
| Wednesday, January 1, 2020 | 357700000 | 1829537000 |
| Friday, January 1, 2021 | 540100000 | 3051100000 |
| Saturday, January 1, 2022 | 322900000 | 2540300000 |
| Sunday, January 1, 2023 | 408000000 | 3162900000 |
| Monday, January 1, 2024 | 3630300000 |
Unleashing the power of data
In the competitive world of biopharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Vertex Pharmaceuticals consistently outpaced United Therapeutics in R&D spending, with an average annual increase of approximately 15%. By 2023, Vertex's R&D expenses had surged to over 3.16 billion, marking a 270% increase from 2014. This robust investment underscores Vertex's aggressive pursuit of groundbreaking therapies.
Conversely, United Therapeutics exhibited a more conservative growth trajectory, with R&D expenses peaking in 2019 at 1.18 billion before stabilizing around 408 million in 2023. This reflects a strategic focus on optimizing existing therapies while selectively investing in new research avenues.
These spending patterns highlight the diverse approaches within the biopharmaceutical industry, where innovation is both a race and a marathon.
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
R&D Insights: How Vertex Pharmaceuticals Incorporated and Viatris Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Viking Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Vertex Pharmaceuticals Incorporated and Novavax, Inc.
Research and Development: Comparing Key Metrics for United Therapeutics Corporation and Summit Therapeutics Inc.
United Therapeutics Corporation or Grifols, S.A.: Who Invests More in Innovation?
United Therapeutics Corporation or Ionis Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Spending Showdown: United Therapeutics Corporation vs Alkermes plc
R&D Insights: How United Therapeutics Corporation and MiMedx Group, Inc. Allocate Funds